Predicting Post-External Beam Radiation Therapy PSA Relapse of Prostate Cancer Using Pretreatment MRI

Journal Article · Mon Nov 01 04:00:00 EDT 2010 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.08.040· OSTI ID:21438004

Fuchsjaeger, Michael H; Pucar, Darko ^[1]; Zelefsky, Michael J ^[2]; Zhigang, Zhang; Qianxing, Mo; Ben-Porat, Leah S ^[3]; Shukla-Dave, Amita ^[1]; Liang, Wang ^[1]; Reuter, Victor E ^[4]; Hricak, Hedvig ^[1]

---

1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
2. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
3. Department of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
4. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (United States)

Purpose: To investigate whether pretreatment endorectal magnetic resonance imaging (MRI) findings can predict biochemical relapse in patients with clinically localized prostate cancer treated with external beam radiation therapy (EBRT). Methods and Materials: Between January 2000 and January 2002, 224 patients (median age, 69 years; age range, 45-82 years) with biopsy-proven prostate cancer underwent endorectal MRI before high-dose ({>=}81Gy) EBRT. The value of multiple clinical and MRI variables in predicting prostate-specific antigen (PSA) relapse at 5 years was determined by use of univariate and multivariate stepwise Cox regression. Clinical variables included pretreatment PSA, clinical T stage, Gleason score, use of neoadjuvant hormonal therapy, and radiation dose. Magnetic resonance imaging variables, derived from retrospective consensus readings by two radiologists, were used to measure intraprostatic and extraprostatic tumor burden. Results: After a median follow-up of 67 months, PSA relapse developed in 37 patients (16.5%). The significant predictors of PSA relapse on univariate analysis were pretreatment PSA, clinical T stage, and multiple MRI variables, including MRI TN stage score; extracapsular extension (ECE) status; number of sextants involved by ECE, all lesions, or index (dominant) lesion; apical involvement; and diameter and volume of index lesion. Pretreatment PSA and ECE status were the only significant independent predictors on multivariate analysis (p < 0.05 for both). Extracapsular extension status was associated with the highest hazard ratio, 3.04; 5-year PSA relapse rates were 7% for no ECE, 20% for unilateral ECE, and 48% for bilateral ECE. Conclusions: Magnetic resonance imaging findings can be used to predict post-EBRT PSA relapse, with ECE status on MRI and pretreatment PSA being significant independent predictors of this endpoint.

• OSTI ID: 21438004
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 78; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BODY
DIAGNOSTIC TECHNIQUES
DISEASES
GLANDS
MALE GENITALS
MATHEMATICS
MEDICINE
MULTIVARIATE ANALYSIS
NEOPLASMS
NMR IMAGING
NUCLEAR MEDICINE
ORGANS
PROSTATE
RADIOLOGY
RADIOTHERAPY
STATISTICS
THERAPY